Prognostic factors of peripheral blood lymphocyte subsets in patients with renal cell carcinoma

Urologia Internationalis

Volumn 57, Issue 1, 1996, Pages 5-10

  Arima, Kiminobu ^a   Nakagawa, Masateru ^b   Yanagawa, Makoto ^a   Sugimura, Yoshiki ^c   Tochigi, Hiromi ^a   Kawamura, Juichi ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Interferon ; Peripheral blood lymphocyte subsets; Prognosis; Recurrence; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; CD8 ANTIGEN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; KIDNEY CARCINOMA; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030036070     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000282868     Document Type: Article

References (14)

1. Quesada JR, Suenson DA; Gutterman JU: Phase study of interferon-alpha in metastatic renal-cell carcinoma: A prognosis report. J Clin Oncol 1985;3:1086-1092.
2. Rober JS: Clinical overview of alpha-intcrferon studies and directions. Cancer 1987:50:997- 1002.
3. Gregory S, Robert F, de Jean K: Interferon in renal cell carcinoma: The UCLA experience. Cancer 1987;59:610-612.
4. Marumo K, Murai M, Hayakawa M, Tazaki H: Human lymphoblastoid interferon therapy for advanced renal cell carcinoma. Urology 1984; 24:567-571.
5. Vugarin D, Hood L, Taylar W, Laszlo J: Phase study of human lymphoblastoid interferon in patients with advanced renal cell carcinoma. Cancer Treat Rep 1985;69:817-820.
6. Kavoussi LR, Levine SR, Kadmon D, Fair W: Regression of metastatic renal cell carcinoma: A case report and literature review. J Urol 1986;135:1005-1007.
7. Kleincrmann ES, Kurzrock R, Wyatt JR, Que-sada JR, Gutterman JU, Fidler IJ: Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant y-interfer-on. Cancer Res 1986;46:5405-5410.
8. Ernstoff MS, Gooding W, Nair S, Bahnson RR, Miketic LM, Banner B, Day R, Whiteside T, Ernstoff LT, Kirkwood M: Immunological effects of treatment with sequential administration of recombinant intcrferon-y and -u in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res 1992;52:851- 856.
9. Kubota S: Lysis of autologous tumor cells by peripheral blood lymphocytes treated with IFN-a in patients with renal cell carcinoma. Jpn J Urol 1992;83:1781-1788.
10. Arirna K, Yanagawa M, Sugimura Y, Tochigi H, Kawamura J, Saitoh K. Yamazaki Y. Mori O. Oomoto Y, Nakagawa M: Effects of nephrectomy and interferon administration on immunological parameters in patients with renal cell carcinoma. Acta Urol Jpn 1994;40: 469-474.
11. Grumstedt B, Wahlquist L: Prognostic significance of clinical angiographic and histological findings in renal carcinoma. Scand J Urol Nephrol 1969;3:117-127.
12. Mims MM, Christenson B, Schlumberger FC, Goodwin WH: A 10-year evaluation of nephrectomy for extensive renal cell carcinoma. J Urol 1966;95:10-15.
13. Onishi T, Machida T, Natori T, Nakagawa M, Matsuoka Y: Immunological effects of intcrfcr-on-alpha or -gamma on patients with renal cell carcinoma. Assessment of effects of these interferons on major histocompatibility complex, tumor-infiltrating lymphocytes and regional lymph node lymphocytes. Cancer J 1992;5: 154-161.
14. Nagase Y, Moriyama N, Hosaka Y, Higashihara E, Murahashi I, Aso Y: Lymphocytic subsets of lumor tissue, nontumorous kidney, and the peripheral blood in primary renal cell carcinoma. JpnJ Urol 1991;82:1781-1789.